GTR Home > Tests > Integrated BRACAnalysis

Overview

Test name

Help

Integrated BRACAnalysis (BRACAnalysis)

Purpose of the test

Help

This is a clinical test intended for Help: Diagnosis, Mutation Confirmation, Pre-symptomatic, Risk Assessment

Condition

Help

1condition tested. Click Indication tab for more information.

Methodology

Help
Molecular Genetics
DDeletion/duplication analysis
Quantitative PCR
CSequence analysis of the entire coding region
Bi-directional Sanger Sequence Analysis

Summary of what tested

2 genes and variants. Click Methodology tab for more information.

Genes and variants

Clinical validity

Help

Not provided

Clinical utility

Help

Not provided

How to order

Help

Licensure is state dependant. All healthcare providers who are licenced to order genetic testing in their state may order this testing.
Order URL Help: https://www.myriadpro.com/

Test services

Help
  • Clinical Testing/Confirmation of Mutations Identified Previously
  • Confirmation of research findings

Suggested reading

  • Phillips et al., 2013
    Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
  • Domchek et al., 2010
    Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality

Clinical resources

Practice guidelines

  • ACMG, 2013
    ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
  • NCCN, 2013
    National Comprehensive Cancer Network practice guidelines in oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian
  • ASCO, 2010
    American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
  • ACOG, 2009
    ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome.
  • NSGC, 2007
    Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors.
  • ACS, 2007
    American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
  • NSGC, 2004
    Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors.
  • ASCO, 2003
    American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Write to the Help Desk